

A SOFTWARE PLATFORM FOR HEALTHCARE APPLICATIONS



NEURISH IS MORE THAN A COMPANY



- I was diagnosed with epilepsy when I was four years old
- I had bad seizures (At one point almost 300 a day)
- I've had two brain surgeries
- I felt isolated and alone
- I struggled to get along with other kids



NEURISH IS MORE THAN A COMPANY



- My degree is in electrical and computer engineering
- I've developed software for several government agencies, healthcare companies, and many other organizations.
- Neurish is my passion and my struggles are my motivation to succeed.
- My team and I are determined to make Neurish a success and will not stop until we get there.

EPILEPSY AS A SOCIAL & ECONOMIC PROBLEM

- Epilepsy and Seizure Disorder patients and caregivers don't have a social support system.
- Pharma and device companies lack a way to improve patients' adherence to prescription medicine and diagnostics
- A national shortage of epilepsy specialists causes doctors to be overworked and patients to be misdiagnosed. It takes years before someone is referred to see an epilepsy specialist.
- Insurance companies spend a lot of money on epilepsy patients

neurish

National Epilepsy Organizations lack a universal way to advocate for their members.

A SUPPORT SYSTEM SOLVES THE PROBLEM











INTRODUCING NEURISH

• We use our proprietary software platform to develop applications that support patients and caregivers.



 FriendsWithEpilepsy.com – A social network for people impacted by epilepsy



• **EpilepsyArticles.com** – A central repository for epilepsy research and news



EpilepsyDocs.com – A yelp type system for rating epilepsy specialists

DATING APP


• **Epilepsy Dating Application** (Under Development) – A dating application specifically for people with epilepsy

MARKET OPPORTUNITY

- A network of 80 million people, with 3.5 million patients and an average network of 22 people supporting them.
- 18 Pharmaceutical and Device Companies seek to improve patients' adherence to prescription medicine and diagnostics
- 6,000 Epilepsy Specialists (A national shortage) seek to provide improved remote service to their patients due to overworked schedules
- 8 Insurance companies providing epilepsy coverage seek to reduce medical spend and improve outcomes
- 50+ National Patient Organizations seek to advocate for their members with The National Epilepsy Foundation being the largest in the U.S.

REVENUE STREAMS

- **Neurish generates**
 - Seizure Management Resources
 - Telemedicine
 - Rewards Program
 - Social Connections and Quality of Life Improvements
 - Information
 - HEOR Analysis
 - Pharmaceutical Adherence Programs
 - Clinical Trial Participation






MARKET STRATEGY

Acquire users from hospitals





Partner with existing resources



TRACTION

- Recently featured in CIO Views as "The 10 Most Inspiring CEOs Making A Difference in 2021"
- Graduated from NewChip and NeuroLaunch Accelerators
- Prototypes developed with 284 users and growing
- User engagement is growing each month
- Partnership with health economics company
- Partnership with Stanford University
- Partnerships with seizure device companies
- Neurish uses AI technology to analyze data and generate patient reported outcomes for device, insurance, and pharma companies.







MANAGEMENT FORECAST ANALYTICS

- Revenue Growth CAGR 62%
- Gross Margin CAGR 65%
- Marketing Spend CAGR 70%
- G&A CAGR 37%
- EBITDA CAGR 79%

- The Neurish business is a technology and marketing driven business.
- The cost of technology grows in pace with the growth in revenue mirrored by the growth in users
- The growth in the cost of marketing and communication lead the growth in revenue
- G&A expenses are kept low reflecting effective management systems and controls



COMPARABLES: Triple Digit Growth !!!

		User Growth		Technology spend	Marketing spend	Share Price (Growth Growth	
		Rate YOY		% of Revenue	% of Revenue	Rate YOY		
<u>Catsys</u>		142%		66%	40%	388%		
	Mar-20	75,000	members					
	Jun-19	31,000	members			Share Price		
	4 insurance comp	any customer	rs constitute	91% of revenue		\$ 13.70	Aug 24 2019	
						\$ 66.90	August 24 2020	
		User Growth	Techn	Technology spend	Marketing spend	Share Price (<u>Growth</u>	
		Rate YOY		% of Revenue	% of Revenue	Rate YOY		
<u>Livongo</u>		98%		27%	46%	355%		
<u>vorigo</u>	Mar-20		members	2770	4070	Share Price		
	Mar-19		members				August 28 2019	
	1328 clients						August 24,2020	
	4 of 7 largest hea	lth plans						
	150 (30%) of fortune 500 companies							
		User Growth		Technology spend	Marketing spend	Share Price (<u>Growth</u>	
		Rate YOY		% of Revenue	% of Revenue	Rate YOY		
<u>neurish</u>	projection			28%	28%	101%		
						Share Price f	orecast	
	Oct-20						October 15 2020	
	Oct-21						October 15 2021	
YEAR 1	3600 Enrollment							
YEAR 1	6 Pharmaceutical and Device Companies							
	1 fortune 500 company							



MANAGEMENT FORECAST


		investment		cash flow (EBITDA)				-	
Investment		Investm	ant	Year 1	Year 2	Year 3	Year 4	Year 5	
	EBITDA and Investment for calculation	-\$1,50		\$1,176,037				\$11,998,776	O
	DCF RATE 25%	\$2,50	0,000	42,270,007	φ 2 ,307,307	40, 10 1,1 10	Ψ10, 10 2 ,170	4	
	Investment Value 5 year DCF	\$8,755,787 +/-16 months 147%						160,00	20,0
	Initial Investment Recovery							4	, <i>\(\(\)</i> .
	IRR %							z.C	~ 4 /-
	Investment Share Price	\$	1.50					Mestor	Α.
	Year 5 Share Price	\$	8.00					10	
	Shares outstanding at investment	5,950,000							
		Reveni	ue	\$4,631,582	\$9,304,091	\$16,979,298	\$28,144,531	\$32,218,327	
		Cost of	f Revenue	\$833,266	\$1,655,133	\$2,712,739	\$3,435,989	\$3,728,964	
		Gross	Profit Margin	\$3,798,316	\$7,648,957	\$14,266,559	\$24,708,542	\$28,489,363	
		Marke	ting	\$731,579	\$2,085,000	\$5,152,651	. \$7,728,977	\$8,888,323	
		G&A&	Technology	\$1,890,700	\$3,196,390	\$5,629,762	\$6,547,387	\$7,602,264	
		EBITD/			\$2,367,567				

\$1.5 MILLION INVESTMENT





OUR VISION



Our vision is to help foster learning, faster paths to the right treatment, and access to resources that enable people impacted by chronic conditions to thrive.



THE CORE TEAM



Phil Gattone

- CEO and Cofounder
- Development Lead
- 15+ years of engineering and development experience



Elisha Phoenix

- Cofounder
- Product Design Lead
- 15+ years of UI/UX design experience



Peter Cunningham

- Business Advisor
- Worldwide C-level
 Officer/Director/Consultant
- Experience with PricewaterhouseCoopers, Glaxo Smith Kline, and many other healthcare companies



Unpaid Medical Advisors

 Including epilepsy specialists from the Stanford Epilepsy Center

NOW IS THE TIME

October 2020



June 2020





UNITEDHEALTH GROUP®

September 2019





trialcard®

WE'RE ON A MISSION



PERSEVERANCE COMMITMENT DETERMINATION



THANK YOU



Phil.Gattone@neurish.me www.neurish.me

CONNECT. GROW. THRIVE.